AKT1 and prostate cancer: Mechanistically, we can conclude that UCM 1037 melatonin derivative inhibits androgen-sensitive prostate cancer cells growth, exerts a cytotoxic effect, down-regulates AR levels and Akt activation, possibly via a melatonin receptor-independent mechanism.